Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings

  • The National Medical Products Administration (NMPA) has approved Antengene Corporation Limited's Investigational New Drug Application for a Phase 1 trial of ATG-019 in China.
  • The trial will evaluate the safety and tolerability of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).
  • ATG-019 is a dual PAK4/NAMPT inhibitor developed by Karyopharm Therapeutics Inc KPTI.
  • Antengene reached an exclusive agreement with Karyopharm and obtained the exclusive development and commercialization rights of ATG-019 in Greater China, South Korea, Australia, New Zealand, and ASEAN countries.
  • Antengene is conducting a Phase 1 trial of ATG-019 in Taiwan in patients with advanced NHL and solid tumors and is planning to conduct clinical trials exploring its combination potential with other agents.
  • Price Action: KPTI shares are up 4.95% at $11.66 in the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefscancerNew Drug ApplicationPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!